Results 151 to 160 of about 22,911 (183)

A Validated LC-MSMS Method for the Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma and Renal Replacement Therapy Effluent and Its Application to a Pharmacokinetic Study

open access: yesAnalytical and Bioanalytical Chemistry, 2019
A simple method for the simultaneous quantification of meropenem and the recently approved β-lactamase inhibitor, vaborbactam, in human plasma and renal replacement therapy effluent (RRTE) was developed and validated. This antibiotic combination protects
Jason Roberts   +2 more
exaly   +2 more sources

Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits

Perfusion, 2021
Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i ®
Jeffrey J Cies   +8 more
openaire   +2 more sources

An Update on Existing and Emerging Data for Meropenem-Vaborbactam

Clinical Therapeutics, 2020
The search for new agents to treat multidrug-resistant gram-negative bacterial infections has been ongoing. Specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections often exhibit multiple resistance mechanisms, including alterations in drug structure, bacterial efflux pumps, and drug permeability.
Bethany R, Shoulders   +2 more
openaire   +2 more sources

An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter species, and Enterobacter species.
Lauren M. Groft   +2 more
openaire   +2 more sources

In Vitro Activity of Meropenem/Vaborbactam and Characterisation of Carbapenem Resistance Mechanisms Among Carbapenem-Resistant Enterobacteriaceae From the 2015 Meropenem/Vaborbactam Surveillance Programme

International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Rodrigo E Mendes   +2 more
exaly   +3 more sources

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho   +3 more
openaire   +2 more sources

A Brief Review of a New Antibiotic: Meropenem-vaborbactam

The Senior Care Pharmacist, 2019
Meropenem-vaborbactam is a newly approved antibiotic for complex urinary tract infections and to treat carbapenem-resistant Enterobacteriaceae infections. Its advantage over meropenem is the betalactamase inhibitor which slows bacterial resistance. This medication has been studied in numerous countries and has relatively few side effects.
openaire   +2 more sources

Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections

Drugs of Today, 2017
On August 29, 2017, the United States Food and Drug Administration (FDA) approved meropenem/ vaborbactam fixed combination for the treatment of adults with complicated urinary tract infections (cUTI). The decision was based on substantial preclinical and clinical data, including two recent trials involving hundreds of adults with cUTI.
M W, McCarthy, T J, Walsh
openaire   +2 more sources

Meropenem / Meropenem-vaborbactam

2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire   +2 more sources

Home - About - Disclaimer - Privacy